Annual Accounts Receivable
$114.02 M
+$38.83 M+51.64%
December 31, 2023
Summary
- As of February 25, 2025, ITCI annual accounts receivable is $114.02 million, with the most recent change of +$38.83 million (+51.64%) on December 31, 2023.
- During the last 3 years, ITCI annual accounts receivable has risen by +$103.25 million (+959.19%).
- ITCI annual accounts receivable is now at all-time high.
Performance
ITCI Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$145.61 M
-$106.00 K-0.07%
September 30, 2024
Summary
- As of February 25, 2025, ITCI quarterly accounts receivable is $145.61 million, with the most recent change of -$106.00 thousand (-0.07%) on September 30, 2024.
- Over the past year, ITCI quarterly accounts receivable has increased by +$42.94 million (+41.82%).
- ITCI quarterly accounts receivable is now -0.07% below its all-time high of $145.71 million, reached on June 30, 2024.
Performance
ITCI Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ITCI Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +51.6% | +41.8% |
| 3 y3 years | +959.2% | +41.8% |
| 5 y5 years | - | +41.8% |
ITCI Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +465.7% | -0.1% | +622.4% |
| 5 y | 5-year | at high | -100.0% | -0.1% | -100.0% |
| alltime | all time | at high | -100.0% | -0.1% | -100.0% |
Intra-Cellular Therapies Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $145.61 M(-0.1%) |
| Jun 2024 | - | $145.71 M(+11.1%) |
| Mar 2024 | - | $131.16 M(+15.0%) |
| Dec 2023 | $114.02 M(+51.6%) | $114.02 M(+11.1%) |
| Sep 2023 | - | $102.67 M(+7.0%) |
| Jun 2023 | - | $95.96 M(+17.7%) |
| Mar 2023 | - | $81.55 M(+8.5%) |
| Dec 2022 | $75.19 M(+273.0%) | $75.19 M(+22.2%) |
| Sep 2022 | - | $61.54 M(+31.0%) |
| Jun 2022 | - | $46.98 M(+43.1%) |
| Mar 2022 | - | $32.83 M(+62.9%) |
| Dec 2021 | $20.16 M(+87.2%) | $20.16 M(+19.0%) |
| Sep 2021 | - | $16.93 M(+11.5%) |
| Jun 2021 | - | $15.19 M(+11.2%) |
| Mar 2021 | - | $13.66 M(+26.9%) |
| Dec 2020 | $10.76 M | $10.76 M(+43.9%) |
| Sep 2020 | - | $7.48 M(+217.9%) |
| Jun 2020 | - | $2.35 M(+74.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $1.35 M(>+9900.0%) |
| Dec 2019 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2017 | - | $6300.00(-89.8%) |
| Jun 2017 | - | $61.90 K(-9.2%) |
| Mar 2017 | - | $68.20 K(-27.7%) |
| Dec 2016 | $94.30 K(+207.2%) | $94.30 K(+7153.8%) |
| Sep 2016 | - | $1300.00(-98.7%) |
| Jun 2016 | - | $98.20 K(+219.9%) |
| Dec 2015 | $30.70 K(-40.5%) | $30.70 K(>+9900.0%) |
| Sep 2015 | - | $0.00(-100.0%) |
| Jun 2015 | - | $9100.00(+175.8%) |
| Mar 2015 | - | $3300.00(-93.6%) |
| Dec 2014 | $51.60 K(-84.7%) | $51.60 K(-58.5%) |
| Sep 2014 | - | $124.40 K(-43.2%) |
| Jun 2014 | - | $219.20 K(+30.6%) |
| Mar 2014 | - | $167.80 K(-50.1%) |
| Dec 2013 | $336.30 K | $336.30 K(+33.8%) |
| Sep 2013 | - | $251.30 K |
FAQ
- What is Intra-Cellular Therapies annual accounts receivable?
- What is the all time high annual accounts receivable for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual accounts receivable year-on-year change?
- What is Intra-Cellular Therapies quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly accounts receivable year-on-year change?
What is Intra-Cellular Therapies annual accounts receivable?
The current annual accounts receivable of ITCI is $114.02 M
What is the all time high annual accounts receivable for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual accounts receivable is $114.02 M
What is Intra-Cellular Therapies annual accounts receivable year-on-year change?
Over the past year, ITCI annual accounts receivable has changed by +$38.83 M (+51.64%)
What is Intra-Cellular Therapies quarterly accounts receivable?
The current quarterly accounts receivable of ITCI is $145.61 M
What is the all time high quarterly accounts receivable for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly accounts receivable is $145.71 M
What is Intra-Cellular Therapies quarterly accounts receivable year-on-year change?
Over the past year, ITCI quarterly accounts receivable has changed by +$42.94 M (+41.82%)